SABCS 2019: New Insights in BC

CME

New Insights in Breast Cancer: Independent Conference Coverage of SABCS 2019

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 02, 2020

Expiration: March 01, 2021

Sara Hurvitz
Sara Hurvitz, MD
Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Activity

Progress
1
Course Completed

In these highlights from the ClinicalThought program, Sara Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD; and Sara Tolaney, MD, MPH, discuss key findings in breast cancer presented at the 2019 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) across multiple settings, including HER2-positive disease and hormone receptor (HR)–positive/HER2-negative breast cancer, along with chemotherapy-based treatment strategies.

CCO plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once prior to the discussion that informs the best choice and then once again after that specific discussion. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with breast cancer do you provide care for in a typical month?

A 59-year-old woman with ER-negative, HER2-positive breast cancer and metastases to her bones received first-line docetaxel/trastuzumab/pertuzumab (THP). She subsequently developed liver lesions and received second-line ado-trastuzumab emtansine (T-DM1). After 8 months on T-DM1, her disease progressed, with new liver metastases and progressive bone metastases.

In your current practice, which of the following approved treatment options would you recommend for this patient?

In the phase II ATEMPT trial evaluating adjuvant T-DM1 in patients with lower-risk, stage I HER2-positive early breast cancer (EBC), which of the following safety outcomes was reported for T-DM1 compared with the standard-of-care adjuvant regimen of paclitaxel plus trastuzumab?

You are referred a patient with newly diagnosed, early-stage triple-negative breast cancer (TNBC) who is seeking a second opinion. She has stage IIIA disease (T2N2). While you are counseling her about her options, she asks if immunotherapy would be a good treatment option for her.

In your response, you mention the phase III KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy in patients with newly diagnosed early-stage TNBC. Which of the following would you tell her based on the pathologic CR (pCR) results reported from this trial?